Pivotal bioVenture Partners Investment Advisor LLC
Long book
$279.8M
Q1 2026
Positions
13
Top-10 weight
98%
concentration
Last quarter
-1.0%
SPY +14.8%
Turnover
21%
of book per quarter
Strategy in plain words
auto-generated from filingsPivotal bioVenture Partners Investment Advisor LLC is a concentrated fundamental stock-picker, specialised in healthcare (100% of the long book), running a $279.8M US long book across 13 positions.
The portfolio is extremely concentrated — the top 10 positions are almost the whole book. Turnover is modest: positions are typically held for years. Current anchor positions: VAXCYTE INC, OCULIS HOLDING AG, EVOMMUNE INC, ARCUTIS BIOTHERAPEUTICS INC, TREVI THERAPEUTICS INC.
Over the last 9 quarters its long book ran on average 2.5pp per quarter ahead of the S&P 500, beating the index in 4 of 9 quarters. We rate its filings highest-signal: new buys here are worth attention.
Implied long-book return vs S&P 500
methodology: positions priced quarterly, no shorts/options Fund long book S&P 500
Q1 2024
+2.7%
Q2 2024
+30.8%
Q3 2024
-12.7%
Q4 2024
-20.0%
Q1 2025
-4.1%
Q2 2025
+17.9%
Q3 2025
+38.1%
Q4 2025
+11.2%
Q1 2026
-1.0%
Sector allocation
Healthcare 100%
Long book by quarter
What does Pivotal bioVenture own?
Q1 2026 13F| Company | Sector | Shares | Value | % of book | Change |
|---|---|---|---|---|---|
| PCVX VAXCYTE INC | Healthcare | 1.4M | $79.8M | 28.5% | Held |
| OCS OCULIS HOLDING AG | Healthcare | 1.7M | $44.7M | 16.0% | -26.6% |
| EVMN EVOMMUNE INC | Healthcare | 1.9M | $44.3M | 15.8% | Held |
| ARQT ARCUTIS BIOTHERAPEUTICS INC | Healthcare | 1.4M | $31.9M | 11.4% | -0.8% |
| TRVI TREVI THERAPEUTICS INC | Healthcare | 1.6M | $18.5M | 6.6% | +23.6% |
| IMNM IMMUNOME INC | Healthcare | 732.5K | $16.0M | 5.7% | Held |
| MPLT MAPLIGHT THERAPEUTICS INC | Healthcare | 611.4K | $12.4M | 4.4% | Held |
| ZBIO ZENAS BIOPHARMA INC | Healthcare | 592.0K | $11.6M | 4.1% | Held |
| BIOA BIOAGE LABS INC | Healthcare | 653.4K | $11.4M | 4.1% | Held |
| AVTX AVALO THERAPEUTICS INC | Healthcare | 295.9K | $4.4M | 1.6% | New |
| RLYB RALLYBIO CORP | Healthcare | 300.6K | $2.7M | 1.0% | New |
| RXRX RECURSION PHARMACEUTICALS-A | Healthcare | 595.5K | $1.8M | 0.7% | Held |
| BOLT BOLT BIOTHERAPEUTICS INC | Healthcare | 42.6K | $172K | 0.1% | -55.0% |
13F filing history
| Period | Form | Filed | Entries | Reported value | Flags | Source |
|---|---|---|---|---|---|---|
| Q1 2026 | 13F-HR | May 14, 2026 | 13 | $279.8M | canonical | SEC ↗ |
| Q4 2025 | 13F-HR | Feb 13, 2026 | 12 | $258.7M | canonical | SEC ↗ |
| Q3 2025 | 13F-HR | Nov 13, 2025 | 10 | $173.0M | canonical | SEC ↗ |
| Q2 2025 | 13F-HR | Aug 13, 2025 | 12 | $161.3M | canonical | SEC ↗ |
| Q1 2025 | 13F-HR | May 14, 2025 | 11 | $123.6M | canonical | SEC ↗ |
| Q4 2024 | 13F-HR | Feb 13, 2025 | 11 | $148.1M | canonical | SEC ↗ |
| Q3 2024 | 13F-HR | Nov 13, 2024 | 11 | $168.5M | canonical | SEC ↗ |
| Q2 2024 | 13F-HR | Aug 13, 2024 | 10 | $130.1M | canonical | SEC ↗ |
| Q1 2024 | 13F-HR | May 14, 2024 | 11 | $155.6M | canonical | SEC ↗ |